CCR2 and peritonitis: Blocking their recruitment to inflamed tissues, using nanoparticules that induce apoptosis (3) or that contain si-RNA against CCR2 (4), reduces inflammation and improves the pathogeny in mouse models of colitis, peritonitis, and atherosclerosis.